A comparative QSAR analysis of substituted imidazolones derivatives as angiotensin II AT1 receptor antagonists

Ajmani S, Jadhav K, Kulkarni SA (2006) Three-Dimensional QSAR using the k-Nearest Neighbor method and its interpretation. J Chem Inf Model 46:24–31 Baumann K (2002) An alignment-independent versatile structure descriptor for QSAR and QSPR based on the distribution of molecular features. J Chem Inf Comput Sci 42:26–35 Bernhart CA, Perreaut PM, Ferrari BP, Muneaux YA, Assens Jean-Louis A, Clement J, Haudricourt F, Muneaux CF, Taillades JE, Marie-A Vignal, Gougat J, Guiraudou PR, Lacour CA, Roccon A, Cazaubon CF, Jean-C Brelihre, Le Fur G, Nisato DA (1993) New Series of Imidazolones: highly Specific and Potent Nonpeptide AT1 Angiotensin II Receptor Antagonists. J Med Chem 36:3311–3380 Clark M, Cramer RD III, Van ON (1989) Validation of the general purpose tripos 5.2 force field. J Comput Chem 10:982–1012 Cramer RD III, Bunce JD, Patterson DE (1988) Cross validation, bootstrapping, and partial least squares compared with multiple regression in conventional QSAR studies. Quant Struct Act Relat 7:18–25 De Gasparo M, Catt KJ, Inagami T, Wright JW, Unger T (2000) International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev 52:415–472 Golbraikh A, Tropsha A (2002) Predictive QSAR modeling based on diversity sampling of experimental datasets for the training and test set selection. J Comput Aided Mol Des 16:357–369 Halgren TA (1996) Merck molecular force field. III. Molecular geometries and vibrational frequencies for MMFF94. J Comput Chem 17:553–586 Israili ZH (2000) Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension. J Hum Hypertens 14(Suppl. 1):S73–S86 Johnston CI (1992) Renin-angiotensin system: a dual tissue and hormonal system for cardiovascular control. J Hypertens 10:S13–S26 Klebe G, Abraham U, Mietzner T (1994) Molecular similarity indices in a comparative analysis (COMSIA) of drug molecules to correlate and predict their biological activity. J Med Chem 37:24–30 Li YP, Weng X, Ning FX, Ou JB, Hou JQ, Luo HB, Li D, Huang ZS, Huang SL, Gu LQ (2013) 3D-QSAR stud-ies of azaoxoisoaporphine, oxoaporphine, and oxoisoaporphine derivatives asanti-AChE and anti-AD agents by the CoMFA method. J Mol Graph Model 41:61–67 Menard J, Bouhnik J, Clauser E, Richoux JP, Corval O (1983) Biochemistry and regulation of angiotensinogen. Clin Exp Hypertens A 5:1005–1019 Moorthy NSHN, Ramos MJ (2011) Fernandes PA (2011) Structural analysis of α-glucosidase inhibitors by validated QSAR models using topological and hydrophobicity based descriptors. Chem Intel Lab Sys 109:101–112 Nahmias C, Strosberg AD (1995) The angiotensin AT2 receptor searching for signal-transduction pathways and physiological function. Trends Pharmacol Sci 16:223–225 Politi A, Durdagi S, Moutevelis-Minakakis P, Kokotos G, Papadopoulos MG, Mavromoustakos T (2009) Application of 3D QSAR CoMFA/CoMSIA and in silico docking studies on novel renin inhibitors against cardiovascular diseases. Eur J Med Chem 44:3703–3711 Richon AB (1997) Young SS an introduction to QSAR methodology. Netw Sci Corp, Saluda Stoll M, Unger T (2001) Angiotensin and its AT2 receptor: new insights into an old system. Regul Pept 99:175–182 Todeschini R, Consonni V, Gramatica P (2009) Chemometrics in QSAR. Comprehen-sive Chemometrics. Chem Biochem Data Ana 4:129–172 Vallotton MB (1987) The Renin-Angiotensin System. Trends Pharmacol Sci 8:69 VLife MDS 3.5 (2008) Molecular design suite. Vlife Sciences Technologies Pvt. Ltd., Pune